Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1032P encodes a pseudogene of the U6 small nuclear RNA family and does not produce a functional protein or RNA product involved in standard cellular processes[1]. U6 snRNA is an essential component of the spliceosome—the complex responsible for intron removal in pre-mRNA splicing—but pseudogenes like RNU6-1032P are generally classified as nonfunctional genomic relics derived from the duplication or mutation of functional genes. Some pseudogenes can influence gene expression indirectly by acting as competing endogenous RNAs or sources of regulatory RNA (such as siRNA or miRNA decoys), but there is no evidence to suggest that RNU6-1032P has such functions[4]. RNU6-1032P is not a therapeutic target, receptor, enzyme, or transporter. It is listed in genetic databases as a transcribed or untranscribed pseudogene with no characterized biological role or clinical relevance at this time[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1032, pseudogene (RNU6-1032P).